US Patent 5,545,405: Claims, scope, validity pressure points, and US landscape
US Patent 5,545,405 has a narrow structural hook in the method claim: a cancer treatment method using a recombinant human/chimeric CDR-grafted or bispecific antibody that is whole-glycosylated, where the improvement is that the antibody is glycosylated by Chinese hamster ovary (CHO) cells. The dependent claims then narrow target disease areas (non-Hodgkin lymphoma, multiple myeloma), target cell types/markers (T-cell marker; specifically anti-CDw52), and cancer-associated antigens (anti-CD33 or anti-CD38), plus dosing and duration.
This creates an unusual combination of (i) broad therapeutic vehicle language (whole glycosylated recombinant human/chimeric CDR-grafted/bispecific antibody “effective in treating said cancer”) and (ii) a specific manufacturing attribute (CHO glycosylation) that can become the fulcrum for both infringement and invalidity arguments, depending on how the prior art and product glycoprotein origin map to the claim.
What do the independent and dependent claims actually cover?
Claim 1: the core infringement and novelty test
Claim 1 requires every element below in a single method claim:
- Administration to a human suffering from cancer.
- Therapeutically effective amount of a whole glycosylated recombinant human, chimeric, CDR grafted, or bispecific antibody “effective in treating said cancer.”
- “Improvement” means the antibody is glycosylated by a Chinese hamster ovary cell.
Practical consequence: In infringement terms, the method is not limited by the antigen target in the independent claim. The target is “said cancer,” and the antibody must be “effective in treating said cancer.” The manufacturing attribute (CHO glycosylation) is the key qualifier that can distinguish prior art products and processes.
Claim 2: non-Hodgkin lymphoma
Adds disease specificity. It is a method limitation on the indication.
Claim 3: multiple myeloma
Adds disease specificity.
Claim 4-5: T-cell marker and anti-CDw52
- Claim 4 narrows “cancer cell marker antigen” direction into the antibody recognizing a T cell marker.
- Claim 5 specifies anti-CDw52.
Practical consequence: This creates a channel for mapping to CDw52-directed therapies and CD52 biology, but it also introduces interpretive risk if the construed “T cell marker” is litigated against the claimed marker/epitope taxonomy.
Claim 6-7: cancer marker antigen and anti-CD33 or anti-CD38
- Claim 6 requires recognition of a cancer cell marker antigen.
- Claim 7 specifies anti-CD33 or anti-CD38.
Practical consequence: These are widely known hematologic targets. If the claim is read broadly on “anti-CD33” and “anti-CD38,” many established antibodies could fall into the claim family conceptually, but the CHO glycosylation constraint remains a major gating element.
Claim 8-9: dose and treatment duration
- Daily dose about 1 mg to 10 mg
- Duration about 1 to 30 days
Practical consequence: These are narrow operational parameters that can affect both infringement coverage (for products with different dosing regimens) and enforceability (for method validity if prior art includes similar dose windows).
How strong is the “CHO glycosylated” hook?
Why the CHO attribute matters
Glycosylation is part of antibody structure and function. The claim does not require a particular glycoform profile or structural variant; it requires that the antibody is glycosylated by CHO cells. That means:
- If an accused antibody is produced in CHO (upstream expression system), infringement coverage can be triggered even if glycan patterns are engineered within CHO systems.
- If the accused product is produced in other expression systems (NS0, SP2/0, human cell lines, yeast), the CHO limitation is a potential non-infringement lever.
Where the claim is vulnerable
The vulnerability is not the existence of CHO as such. The vulnerability is whether, at the time of filing, prior art already disclosed:
- recombinant antibodies for cancer treatment with “whole glycosylation,” and
- production in CHO cell lines, and
- sufficiently similar dosing regimens and indications.
If prior art disclosed cancer antibody therapy using CHO-produced glycosylated antibodies, the “improvement” language may be attacked as obvious or as lacking patentable distinction, especially since CHO glycosylation is a common industry practice for therapeutic antibodies.
Claim chart logic: element-by-element mapping for infringement
Below is a practical mapping framework for evaluating whether a specific product could fall within the claim language.
| Claim element |
What must be proven in a US infringement case |
High-friction aspects |
| Administer therapeutically effective amount |
Clinical administration evidence |
depends on regimen labeling and practice |
| “Whole glycosylated recombinant human/chimeric CDR grafted or bispecific antibody” |
Antibody is glycosylated across the molecule consistent with the claimed “whole” language |
“whole glycosylated” is vague; may invite claim construction |
| Effective in treating “said cancer” |
Indication relevance and/or efficacy |
broad “effective” language can reduce friction |
| Improvement: glycosylated by CHO cells |
Manufacturing evidence (host cell) |
easiest to obtain via biologics CMC disclosures; strong binary outcome |
| Dependent: non-Hodgkin lymphoma or multiple myeloma |
Indication limitation |
differs by drug label and trial use |
| Dependent: anti-CDw52, anti-CD33, anti-CD38 |
Antigen/epitope recognition |
interpretive issues around marker definition and binding specificity |
| Dose/day and duration |
Dosing schedule matches about 1 to 10 mg/day and 1 to 30 days |
regimen mismatch can avoid method claim |
Patent landscape: where US 5,545,405 likely sits and why
A complete “comprehensive and critical analysis” of the US landscape requires the full publication timeline and family data for US 5,545,405 and its competitors (including priority, assignee, claim sets, prosecution history, and related continuations). That record is not provided here. Under the operating constraints, this response cannot produce a complete, accurate landscape map or cite specific later or concurrent US patents with reliable linkage.
What can be stated critically from the claim language alone is the competitive topology:
1) The landscape risk is highest for CHO-manufactured cancer antibodies
Because the CHO limitation is the main distinguishing feature, competitors using CHO expression systems for glycosylated recombinant antibodies create the most exposure risk, regardless of whether the antigen target aligns with the dependent claims. The independent claim reads onto “effective in treating said cancer,” which can broaden the theater.
2) Dependent claims tie to well-known hematology targets
The presence of:
- anti-CDw52 (often associated with CD52-directed immunotherapy),
- anti-CD33 (AML/myeloid target),
- anti-CD38 (multiple myeloma target),
signals that enforcement activity likely targets products in hematologic oncology.
3) The dose/duration limits create partial carve-outs
Even if an antibody is CHO glycosylated and has the same target, method coverage may fail if real-world dosing is outside:
- 1 mg to 10 mg per day
- 1 to 30 days
This is a common attack line in method claim enforcement, since biologics regimens frequently use cycles, weight-based dosing, and intermittent schedules rather than continuous daily administration for 30 days.
Validity pressure points under US law (critical view of claim 1)
A. Obviousness: CHO glycosylation was routine
If prior art disclosed glycosylated recombinant antibodies for cancer that are produced in CHO cells, then claim 1’s “improvement” may be attacked as routine optimization rather than a non-obvious technical contribution. The claim does not specify a novel glycoengineering step beyond using CHO cells.
B. Claim breadth: “whole glycosylated” and “effective in treating said cancer”
Broad functional language often creates a challenge:
- The claim could read on antibodies whose therapeutic effect at the claimed indication is not inherent.
- During litigation, the patentee must still satisfy enablement and written description requirements for the full scope of targets implied by “said cancer.”
C. Indefiniteness or construction risk
Terms like “whole glycosylated” can be litigated:
- If “whole” is construed as requiring glycosylation at all glycosylation sites, many antibodies could fall outside.
- If construed more loosely as “glycosylated antibody” generally, then the limitation ceases to meaningfully differentiate from prior art.
D. Dependent claim vulnerabilities
- Anti-CDw52 / anti-CD33 / anti-CD38 are specific. If prior art includes CHO-produced anti-CDw52/33/38 antibodies for the same therapeutic indications, dependent claims may be more directly invalidated by obviousness or anticipation.
- Dose/duration claims may be invalidated if prior art includes similar dosing windows, or avoided in infringement if actual regimens differ.
Business implications for R&D and investment
Enforcement posture depends on manufacturing evidence
For method claims hinging on CHO glycosylation, infringement outcomes tend to turn on host-cell evidence rather than deep epitope engineering. That means:
- product comparability and CMC transparency become central diligence inputs,
- and biosimilar or next-gen candidates using CHO may carry higher legal exposure if they fall into the same antigen and indication windows.
Development strategy should stress regimen and indication
Given dose/day and duration limits, counsel and development teams typically evaluate:
- whether planned regimens align with “about 1 to 10 mg/day” and “about 1 to 30 days,”
- whether the primary indication is within non-Hodgkin lymphoma or multiple myeloma as written,
- and whether the target antigen maps cleanly to anti-CDw52, anti-CD33, or anti-CD38.
Portfolio risk rises for CHO-made hematology antibodies
The dependent claim target list is confined to hematologic markers. In practice, that concentrates both the market and the legal risk to a subset of oncology biologics with CD52/CD33/CD38 mechanisms.
Key Takeaways
- US 5,545,405 is a method claim anchored on a manufacturing qualifier: the administered antibody is glycosylated by CHO cells.
- Independent claim breadth is high on “effective in treating said cancer,” while dependent claims narrow to non-Hodgkin lymphoma, multiple myeloma, and specific antigens (CDw52/CD33/CD38), plus dose/day and duration windows.
- The CHO glycosylation hook is likely the principal differentiator for infringement, but it is also the principal obviousness vulnerability if CHO-produced glycosylated cancer antibodies were known.
- From an operational standpoint, infringement and freedom-to-operate are most sensitive to host-cell production and regimen alignment with the claimed dose/duration constraints.
FAQs
1) What is the main novelty driver in US 5,545,405?
Claim 1’s “improvement” is that the antibody is glycosylated by Chinese hamster ovary (CHO) cells.
2) Does the independent claim require a specific target antigen?
No. Claim 1 requires an antibody “effective in treating said cancer,” and the specific antigen targets appear only in dependent claims.
3) Which diseases are explicitly covered in dependent claims?
Non-Hodgkin lymphoma (claim 2) and multiple myeloma (claim 3).
4) Which antigen targets appear in dependent claims?
Anti-CDw52 (claim 5) and anti-CD33 or anti-CD38 (claims 7).
5) Can differing dosing schedules avoid claim coverage?
Potentially. The method is limited to about 1 to 10 mg/day and about 1 to 30 days (claims 8-9).
References
- United States Patent 5,545,405 (claim text as provided in prompt).
